Synergy Laboratories, INC.

Synergy Laboratories, INC. was paid $10.29M by Medicaid between Jan 2018 and Dec 2024, across 123 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 23% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Alabama

Rank by total paid#10 of 61

Median peer was paid$46K

This provider vs. median226×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	27,323	$988K
2019	33,567	$1.15M
2020	61,498	$2.57M
2021	55,961	$2.14M
2022	58,294	$1.26M
2023	72,024	$1.01M
2024incomplete	95,010	$1.17M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	23%	41,296	21,422	$2.32M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	16%	22,999	21,908	$1.67M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	15%	34,997	32,849	$1.52M
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	5.5%	12,857	11,186	$568K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	4.9%	12,271	11,255	$502K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	4.4%	4,049	3,442	$452K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	2.7%	7,517	3,730	$282K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.7%	2,216	2,125	$174K
84443	Thyroid stimulating hormone (TSH)	1.6%	12,953	11,372	$169K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.5%	9,189	8,057	$157K
80053	Comprehensive metabolic panel	1.4%	17,366	14,823	$144K
80081		1.2%	2,248	2,103	$126K

111 more codes

82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.1%	6,008	$114K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.1%	17,236	$113K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.1%	8,431	$113K
87511		1.1%	5,716	$111K
87481		1.0%	5,402	$106K
87631		1.0%	1,979	$104K
80061	Lipid panel	<1%	10,091	$90K
83036	Hemoglobin; glycosylated (A1C)	<1%	10,563	$84K
87088		<1%	10,265	$71K
87086	Culture, bacterial; quantitative colony count, urine	<1%	10,245	$71K
82607		<1%	5,550	$68K
87640		<1%	4,210	$68K
87529		<1%	2,247	$63K
86780		<1%	5,376	$61K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	3,316	$56K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	457	$55K
86762		<1%	3,151	$41K
84439		<1%	6,239	$40K
86803		<1%	3,381	$40K
87186		<1%	3,975	$30K
87340		<1%	3,207	$29K
82728		<1%	2,865	$28K
80074		<1%	801	$27K
85027		<1%	7,212	$26K
86592		<1%	7,025	$24K
87077		<1%	3,621	$24K
87541		<1%	871	$21K
87486		<1%	869	$21K
87581		<1%	870	$21K
87532		<1%	869	$21K
87496		<1%	867	$20K
86850		<1%	3,259	$20K
82746		<1%	2,110	$20K
82668		<1%	1,314	$19K
83550		<1%	2,664	$19K
84480		<1%	1,207	$17K
87081		<1%	2,822	$16K
86235		<1%	150	$16K
83540		<1%	2,720	$15K
84702		<1%	1,728	$14K
82670		<1%	817	$14K
83735		<1%	2,454	$14K
87015		<1%	3,212	$14K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	3,414	$13K
83001		<1%	941	$13K
84403		<1%	685	$13K
87653		<1%	805	$12K
84153		<1%	998	$11K
82570		<1%	2,720	$11K
87076		<1%	1,456	$10K
82105		<1%	594	$9K
82947		<1%	3,046	$9K
84146		<1%	629	$9K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	83	$8K
84144		<1%	495	$6K
82950		<1%	1,507	$6K
84402		<1%	306	$6K
80048	Basic metabolic panel (calcium, ionized)	<1%	966	$6K
86900		<1%	2,567	$6K
84481		<1%	498	$6K
86901		<1%	2,507	$6K
82043		<1%	1,419	$5K
82550		<1%	816	$5K
82951		<1%	761	$5K
84466		<1%	434	$5K
85045		<1%	1,413	$4K
86709		<1%	384	$4K
84156		<1%	1,559	$4K
81015		<1%	1,756	$4K
83002		<1%	296	$4K
86705		<1%	319	$4K
85651		<1%	1,153	$4K
80050	General health panel	<1%	246	$4K
80055		<1%	97	$3K
87071		<1%	768	$3K
86696		<1%	226	$3K
81001		<1%	1,154	$3K
87563		<1%	1,607	$3K
86695		<1%	227	$3K
86706		<1%	204	$2K
86225		<1%	150	$2K
86038		<1%	150	$1K
83516		<1%	150	$1K
83525		<1%	157	$1K
86140		<1%	304	$1K
82677		<1%	42	$945.00
81514		<1%	310	$788.96
87500		<1%	41	$743.82
87205		<1%	146	$652.25
86336		<1%	42	$595.00
84550		<1%	190	$592.77
83698		<1%	16	$462.00
85018		<1%	225	$433.79
85014		<1%	224	$431.79
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	919	$431.40
86376		<1%	43	$407.88
86430		<1%	80	$399.33
84436		<1%	91	$347.13
85007		<1%	131	$327.38
85660		<1%	75	$294.08
83090		<1%	16	$266.00
85049		<1%	100	$252.88
36415	Collection of venous blood by venipuncture	<1%	3,166	$172.91
0065U		<1%	324	$157.50
84681		<1%	14	$156.00
80164		<1%	15	$148.90
87040		<1%	14	$130.00
87102		<1%	15	$87.06
82248		<1%	79	$51.74
82565		<1%	15	$48.00
87799		0%	47	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPITTS, BRADRICK (CEO)